Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study.
- DOI
- 10.3390/biomedicines10092243
- Published
- 2022 Sep 9
- Container
- Biomedicines
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3390/biomedicines10092243,
title = {Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study.},
author = {Yamada T and Nakane K and Enomoto T and Tomioka M and Taniguchi T and Ishida T and Ozawa K and Takagi K and Ito H and Takeuchi S and Kawase M and Kawase K and Kato D and Takai M and Iinuma K and Yokoi S and Nakano M and Koie T},
year = {2022},
journal = {Biomedicines},
doi = {10.3390/biomedicines10092243},
url = {https://doi.org/10.3390/biomedicines10092243}
}RIS
TY - JOUR TI - Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study. AU - Yamada T AU - Nakane K AU - Enomoto T AU - Tomioka M AU - Taniguchi T AU - Ishida T AU - Ozawa K AU - Takagi K AU - Ito H AU - Takeuchi S AU - Kawase M AU - Kawase K AU - Kato D AU - Takai M AU - Iinuma K AU - Yokoi S AU - Nakano M AU - Koie T PY - 2022 JO - Biomedicines DO - 10.3390/biomedicines10092243 UR - https://doi.org/10.3390/biomedicines10092243 ER -
APA
T, Y., K, N., T, E., M, T., T, T., T, I., K, O., K, T., H, I., S, T., M, K., K, K., D, K., M, T., K, I., S, Y., M, N., & T, K. (2022). Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study.. Biomedicines. https://doi.org/10.3390/biomedicines10092243
Source records
- pubmed · retrieved 2026-09-26T15:57:22.360Z